Sorafenib and Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent

Bladder Cancer Clinical Trial

— SOGUG-07-01  

Official title:

Phase I Trial of Sorafenib in Combination With Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00544609
• Other study ID #: SOGUG-07-01
• Status: Completed
• Phase: Phase 1
• First received: October 15, 2007
• Last updated: October 1, 2014
• Start date: December 2007
• Est. completion date: May 2012

Study information

• Verified date: October 2014
• Source: Spanish Oncology Genito-Urinary Group
• Contact: n/a
• Is FDA regulated: No
• Health authority: Spain: Spanish Agency of Medicines
• Study type: Interventional

Clinical Trial Summary

Safety profile and to determine maximum tolerated dose of Sorafenib in combination with Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent

Description:

Study phase I in patients with Invasive Bladder Cancer

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: May 2012
• Est. primary completion date: August 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients diagnosed with urothelial carcinoma of the bladder, in clinical stages T2-4a N0 M0 (if multifocal evaluation of all lesions by biopsies), who are not candidates for radical cystectomy by medical reasons or refusal.

• No prior treatment with radiotherapy to the bladder or systemic chemotherapy.

• Patients must be = 18 years old.

• Patients must have ECOG performance status 0 to 2.

• Life expectancy of at least 12 weeks.

• Patients with adequate bone marrow, hepatic and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening:

hemoglobin = 9.0 g/dl absolute neutrophil count = 1.500/mm3 platelets = 100.000/mm3. total bilirubin = 1.5 times the upper limit of normality SGOT (AST) and/or SGPT (ALT) = 2.5 times the upper limit of normality alkaline phosphatase = 4 x ULN serum creatinine =1.5 upper limit of normality PT-INR/PTT < 1.5 x upper limit of normality creatinine clearance = 40 ml/min using Cockcroft-Gaul

• Patients must give their written informed consent before any procedure related to the study is performed; therefore, it must be given at the selection visit. The patient must be informed that he has the right to withdraw from the study at any time, without any kind of prejudice.

• Patients who are capable of accomplishing the study's requirements and without any impediments to follow the instructions.

• Women of fertile age must have a negative result in the pregnancy test performed 7 days before the beginning of the administration of the study medication.

• Patients from both sexes must use adequate contraceptive methods (oral or injectable contraceptives, intrauterine device, condom, sterilization) whilst participating in the protocol. After the retreat of treatment with sorafenib, the contraceptive methods must be used during 4 weeks in women and during 3 months in men.

Exclusion Criteria:

• Patients with active infection or other serious medical conditions (autologous bone marrow transplant or stem cell rescue within 4 months of study, patients undergoing renal dialysis, known HIV infection or chronic hepatitis B or C, active clinically serious infections > CTCAE Grade 2, non-healing wound, ulcer, or bone fracture).

• Abuse of substances, clinical conditions, psychological or social, that would preclude appropriate informed consent or compliance with protocol.

• Concurrent treatment with other experimental drugs (within 30 days prior to study entry).

• Concurrent treatment with other anti-cancer- or immunotherapy during the study or within 4 weeks of study entry.

• Treatment wuth mitomycin C or nitrosureas during 6 weeks prior of study entry.

• History of prior malignancies within the preceding 5 years other than previously treated basal cell carcinoma of the skin, incipient prostate cancer and in situ cervix carcinoma.

• Pregnant or breast feeding patients.

• Known or suspected allergy to sorafenib.

• Cardiac disease: Congestive heart failure > class II NYHA; active CAD (myocardial infarction more than 6 months to study entry is allowed); cardiac arrythmias requiring anti-arrythmic therapy (beta blockers or digoxin are permitted).

• Uncontrolled hypertension defined as systolic blood pressure > 150 mm Hg or diastolic pressure > 90 mm Hg, despite optimal medical management.

• Known brain metastasis. Patients with neurological symptoms should undergo a CT scan/MRI of the brain to exclude brain metastasis.

• Thrombotic or embolic events such as cerebrovascular accident including transient ischemic attacks within the past 6 months.

• Patients with hydronephrosis.

• Patients with seizure disorder requiring medication (such as steroids or antiepileptics).

• History of organ allograft.

• Patient unable to swallow oral medication.

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Bladder Cancer
• Urinary Bladder Neoplasms

Intervention

Drug:
• Sorafenib
Level 1: 200 mg/day Level 2: 400mg/day Level 3: 800mg/day

Procedure:
• Radiotherapy
3th-8th week: sorafenib daily with radiotherapy day 1, 2, 3, 4 and 5, 9th week: sorafenib daily with radiotherapy day 1 and 2

Locations

Country	Name	City	State
Spain	Hospital Clínic i Provincial de Barcelona	Barcelona
Spain	Hospital de la Santa Creu i Sant Pau	Barcelona
Spain	Institut Català d' Oncología	Barcelona

Sponsors (1)

Lead Sponsor	Collaborator
Spanish Oncology Genito-Urinary Group

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety profile of Sorafenib in combination with Radiotherapy.		12 weeks	Yes
Primary	Maximum tolerated dose of Sorafenib in combination with Radiotherapy.		12 weeks	Yes